miR-122, a paradigm for the role of microRNAs in the liver
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Recent studies have uncovered profound and unexpected roles for a family of tiny regulatory RNAs, known as microRNAs (miRNAs), in the control of diverse aspects of hepatic function and dysfunction, including hepatocyte growth, stress response, metabolism, viral infection and proliferation, gene expression, and maintenance of hepatic phenotype. In liver cancer, misexpression of specific miRNAs suggests diagnostic and prognostic significance. Here, we review the biology of the most abundant miRNA in human liver, miR-122, and consider the diversity of its roles in the liver. We provide a compilation of all miRNAs expressed in the liver, and consider some possible therapeutic opportunities for exploiting miRNAs in the different settings of liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas
Kutay, H., Bai, S., Datta, J., Motiwala, T., Pogribny, I., Frankel, W., Jacob, S. T., & Ghoshal, K. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20982 · Cited by 608
RetractedThe functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Prediction of Mammalian MicroRNA Targets
Lewis, B. P., Shih, I.-H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003) · Cell · doi:10.1016/s0092-8674(03)01018-3 · Cited by 5,199
Identification of Novel Genes Coding for Small Expressed RNAs
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001) · Science · doi:10.1126/science.1064921 · Cited by 4,956
Real-time quantification of microRNAs by stem-loop RT-PCR
Chen, C. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni178 · Cited by 4,952
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626
A microRNA polycistron as a potential human oncogene
He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S. W., Hannon, G. J., et al. (2005) · Nature · doi:10.1038/nature03552 · Cited by 3,483
Cited by
Hammond, S. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.001 · Cited by 1,284
Circulating microRNAs are new and sensitive biomarkers of myocardial infarction
D'Alessandra, Y., Devanna, P., Limana, F., Straino, S., Di Carlo, A., Brambilla, P. G., Rubino, M., Carena, M. C., Spazzafumo, L., De Simone, M., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq167 · Cited by 797
Coulouarn, C., Factor, V. M., Andersen, J. B., Durkin, M. E., & Thorgeirsson, S. S. (2009) · Oncogene · doi:10.1038/onc.2009.211 · Cited by 733
miR-122 – A key factor and therapeutic target in liver disease
Bandiera, S., Pfeffer, S., Baumert, T. F., & Zeisel, M. B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.004 · Cited by 629
Molecular mechanisms of hepatocellular carcinoma
Aravalli, R. N., Steer, C. J., & Cressman, E. N. K. (2008) · Hepatology · doi:10.1002/hep.22580 · Cited by 625
Xu, J., Wu, C., Che, X., Wang, L., Yu, D., Zhang, T., Huang, L., Li, H., Tan, W., Wang, C., et al. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20712 · Cited by 567
Circulating microRNAs as potential markers of human drug-induced liver injury
Starkey Lewis, P. J., Dear, J., Platt, V., Simpson, K. J., Craig, D. G. N., Antoine, D. J., French, N. S., Dhaun, N., Webb, D. J., Costello, E. M., et al. (2011) · Hepatology · doi:10.1002/hep.24538 · Cited by 515
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases
Wang, X., He, Y., Mackowiak, B., & Gao, B. (2021) · Gut · doi:10.1136/gutjnl-2020-322526 · Cited by 495
Bai, S., Nasser, M. W., Wang, B., Hsu, S.-H., Datta, J., Kutay, H., Yadav, A., Nuovo, G., Kumar, P., & Ghoshal, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.016774 · Cited by 477
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Plasma MicroRNA-122 as a Biomarker for Viral-, Alcohol-, and Chemical-Related Hepatic Diseases
Zhang, Y., Jia, Y., Zheng, R., Guo, Y., Wang, Y., Guo, H., Fei, M., & Sun, S. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147850 · Cited by 415
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
“It stands out as one of the initial miRNAs displaying high levels of tissue-specific expression [210]. miR-122 plays a pivotal role in regulating cholesterol and fatty acid metabolism within the adult liver, positioning it as a promising therapeutic target for metabolic diseases [211].”
BackgroundWang, S., Qiu, L., Yan, X., Jin, W., Wang, Y., Chen, L., Wu, E., Ye, X., Gao, G. F., Wang, F., et al. (2012) · Hepatology · doi:10.1002/hep.24809 · Cited by 259
Reexamining assumptions about miRNA-guided gene silencing
Kilikevicius, A., Meister, G., & Corey, D. R. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1256 · Cited by 194
“miR-122 is a case study for targeting miRNAs for therapeutic development (89).”
The crosstalk: exosomes and lipid metabolism
Wang, W., Zhu, N., Yan, T., Shi, Y.-N., Chen, J., Zhang, C.-J., Xie, X.-J., Liao, D.-F., & Qin, L. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00581-2 · Cited by 203
Ghosh, J., Bose, M., Roy, S., & Bhattacharyya, S. N. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.02.005 · Cited by 191
“miR-122 comprises more than 70% of the liver miRNA pool and is largely responsible for liver homeostasis and lipid metabolism (Chang et al., 2004; Girard et al., 2008).”
BackgroundAmeling, S., Kacprowski, T., Chilukoti, R. K., Malsch, C., Liebscher, V., Suhre, K., Pietzner, M., Friedrich, N., Homuth, G., Hammer, E., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0136-7 · Cited by 181
Qiao, C., Yuan, Z., Li, J., He, B., Zheng, H., Mayer, C., Li, J., & Xiao, X. (2011) · Gene Therapy · doi:10.1038/gt.2010.157 · Cited by 163
MicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
“It is one of the earliest miRNAs with tissue-specific and high abundance expression (Girard et al., 2008).”
BackgroundmiR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2
Li, X.-N., Yang, H., & Yang, T. (2020) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504019x15615433287579 · Cited by 34
Retracted
Metadata
- Authors
- Girard, M., Jacquemin, E., Munnich, A., Lyonnet, S., & Henrion-Caude, A.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2008-04
- Volume
- 48
- Issue
- 4
- Pages
- 648-656
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W1976628534
- Cited by
- 375
- References
- 58
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.